Pregnancy of Norephedrane in details
Information related to use of Norephedrane in pregnancy is limited (Maurovich-Horvat 2013). The majority of human data are based on illicit Norephedrane/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse 2012). Newborns should be monitored for agitation, irritability, excessive drowsiness, or feeding difficulties
Data collection to monitor pregnancy outcomes following exposure to Norephedrane is ongoing. Healthcare providers are encouraged to enroll females exposed to Norephedrane during pregnancy in the National Pregnancy Registry for Psychostimulants (1-866-961-2388 and/or https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/).
Norephedrane breastfeeding
Breastfeeding is not recommending during treatment. Excreted into human milk: Yes Comments: -The effect of Norephedrane in milk on the neurological development of the breastfed infant has not been well studied. -Large dosages of Norephedrane might interfere with milk production, especially in women whose lactation is not well established.
-The urinary excretion in a breastfed infant whose mother took Norephedrane 35 mg daily and exclusively breastfed for 6 months ranged from 1.9% to 2.1% of the mother's excretion; this infant experienced no adverse reactions and grew normally, and the mother experienced no adverse effect on milk production. -The urinary excretion in a breastfed infant whose mother took racemic Norephedrane 5 mg four times daily ranged from 0.1% to 0.3% of the mother's excretion; this infant showed no signs of abnormal development during the first 2 years of life. -In a study of 20 postpartum women, dextroamphetamine reduced serum prolactin by 25% to 32% (7.5 mg IV dose) and 30% to 37% (15 mg IV dose). Another study showed a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40%.
See references
References for pregnancy information
- "Product Information. Dyanavel XR (Norephedrane)." Tris Pharma Inc, Monmouth Junction, NJ.
- "Product Information. Evekeo (Norephedrane)." Arbor Pharmaceuticals, Atlanta, GA.
- United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
References for breastfeeding information
- "Product Information. Dyanavel XR (Norephedrane)." Tris Pharma Inc, Monmouth Junction, NJ.
- "Product Information. Evekeo (Norephedrane)." Arbor Pharmaceuticals, Atlanta, GA.
- United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
References
- DailyMed. "AMPHETAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubMed Health. "Amphetamine (By mouth) (Adzenys ER): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
- Human Metabolome Database (HMDB). "Amphetamine: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
